Veeda launches Oncology CRO subsidiary

Image
Announcement Corporate
Last Updated : Feb 05 2013 | 3:36 AM IST

Don't want to miss the best from Business Standard?

* Expected to lead to additional global capacity through targeted acquisitions
 
 
Mumbai: Veeda Clinical Research, a full service Global CRO, announced today the launch of a Global Oncology CRO. The objective of setting up Veeda Oncology is to provide oncology clinical research services internationally for the pharmaceutical and biotech industries. Veeda would leverage its presence in the US, Europe and India to meet both the regional and global needs of its sponsors.
 
 
Announcing the formation of the new Global Oncology subsidiary CRO, Mr. Binoy Gardi, Group Managing Director, Veeda Clinical Research, said "Since July 1, 2007 we have been establishing the infrastructure for a global oncology CRO and today we are pleased to announce that both the personnel and technical infrastructure are in place, validated and tested."
 
 
"I am extremely excited to fulfill a vision of Veeda to be able to provide clients with world class oncology expertise along with rapid and cost effective access to oncology / hematology patients around the globe through our facilities in India, Europe and North America"," said Mr. Matt Bowman, President and CEO of the Oncology Division.    
 
 
Mr. Bowman has over 20 years of clinical oncology experience with major pharma, biotech and oncology CRO companies. "Our headquarters are located in Columbus, Ohio and we have organized a strong leadership team with Mr. Kathy Squillace as Vice President of Clinical Operations and Mr. Dave Colborn as Vice President of Data Management and Information Technology, both of whom has over 20 years of oncology clinical development experience. In addition, we expect additional global capacity through targeted acquisitions that we anticipate completing during the next quarter."
 
 
Apurva Shah, Co- Group Managing Director, Veeda Clinical Research commented, "A key strategy that we are implementing will be our access to the oncology patient population through our unique exclusive relationships with oncology hospitals in India as well as unique relationships with oncology hospitals in Eastern Europe. In addition, our US organization has worked with virtually every major oncology investigational site. With these relationships and the rapid ability to open sites, we will be able to meet the critical accrual requirements that our sponsors are establishing to accelerate the rate of drug development."  
 
 
About Veeda
 
 
Veeda Clinical Research is a vibrant Anglo/India CRO which brings together 20 years of clinical research expertise with the intellectual ability and tireless work ethic of the East. From First-in-Man studies to large scale Bioequivalence/Bioavailability comparator studies Veeda Clinical Research offers a fully integrated package to meet your early clinical development needs.
 
 
With state-of-the-art phase I facilities in Plymouth in the UK, Ahmedabad in India and Görlitz in Germany, fully accredited GLP laboratories, an established biometrics team in Belgium and India and a respected pre-clinical partner, Veeda CR can take your compound from pre-clinical development to proof of concept in the most timely, cost effective manner. For those clients unfamiliar with the benefits of outsourcing to India, or for those who choose to strategically spread their programmes of work between two continents, Veeda CR can deliver significant cost savings combined with the complete reassurance of a UK project management service.
 
 

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 31 2008 | 12:00 AM IST

Next Story